Login Register Cart 0
Generic placeholder image

Recent Advances in Drug Delivery and Formulation

Editor-in-Chief

ISSN (Print): 2667-3878
ISSN (Online): 2667-3886

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Application of D-Optimal Mixture Design in the Development of Nanocarrier-Based Darifenacin Hydrobromide Gel

Author(s): Divya Patel, Maanika Menon, Pranav Shah, Meenakshi Patel and Manisha Lalan*

Volume 17, Issue 1, 2023

Published on: 01 March, 2023

Page: [47 - 60] Pages: 14

DOI: 10.2174/2667387817666230221141501

Price: $65

Abstract

Background: Darifenacin hydrobromide, a BCS Class II drug, is poorly bioavailable due to extensive first-pass metabolism. The present study is an attempt to investigate an alternative route of drug delivery by developing a nanometric microemulsion-based transdermal gel for the management of an overactive bladder.

Methods: Oil, surfactant, and cosurfactant were selected based on the solubility of the drug, and surfactant: cosurfactant in surfactant mixture (Smix) was selected at a 1:1 ratio as inferred from the pseudo ternary phase diagram. The D-optimal mixture design was used to optimize the o/w microemulsion wherein the globule size and zeta potential were selected as dependable variables. The prepared microemulsions were also characterized for various physico-chemical properties like transmittance, conductivity, and TEM. The optimized microemulsion was gelled using Carbopol 934 P and assessed for drug release in vitro and ex vivo, viscosity, spreadability, pH, etc.

Results: Drug excipient compatibility studies showed that the drug was compatible with formulation components. The optimized microemulsion showed a globule size of less than 50 nm and a high zeta potential of -20.56 mV. The ME gel could sustain the drug release for 8 hours as reflected in in vitro and ex vivo skin permeation and retention studies. The accelerated stability study showed no significant change in applied storage conditions.

Conclusion: An effective, stable, non-invasive microemulsion gel containing darifenacin hydrobromide was developed. The achieved merits could translate into increased bioavailability and dose reduction. Further confirmatory in vivo studies on this novel formulation, which is a cost-effective & industrially scalable option, can improve the pharmacoeconomics of overactive bladder management.

« Previous Next »
Graphical Abstract

[1]
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61(1): 37-49.
[http://dx.doi.org/10.1016/S0090-4295(02)02243-4] [PMID: 12559262]
[2]
Meng E, Lin WY, Lee WC, Chuang YC. Pathophysiology of overactive bladder. Low Urin Tract Symptoms 2012; 4(S1): 48-55.
[http://dx.doi.org/10.1111/j.1757-5672.2011.00122.x] [PMID: 26676700]
[3]
Geller E, Dieter A, Willis-Gray M. Evaluation and management of overactive bladder: Strategies for optimizing care. Res Rep Urol 2016; 8: 113-22.
[http://dx.doi.org/10.2147/RRU.S93636] [PMID: 27556018]
[4]
Tomaszewski J. Postmenopausal overactive bladder. Przegl Menopauz 2014; 13(6): 313-29.
[http://dx.doi.org/10.5114/pm.2014.47984] [PMID: 26327873]
[5]
Eapen R, Radomski S. Review of the epidemiology of overactive bladder. Res Rep Urol 2016; 8: 71-6.
[http://dx.doi.org/10.2147/RRU.S102441] [PMID: 27350947]
[6]
Przydacz M, Golabek T, Dudek P, Lipinski M, Chlosta P. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep 2020; 10(1): 19819.
[http://dx.doi.org/10.1038/s41598-020-76846-0] [PMID: 33188254]
[7]
Wagg A. Recent advances in the treatment of urinary incontinence in older women. Curr Opin Urol 2008; 18(4): 383-8.
[http://dx.doi.org/10.1097/MOU.0b013e328302ccc1] [PMID: 18520759]
[8]
Alabaster VA. Discovery & development of selective M3 antagonists for clinical use. Life Sci 1997; 60(13-14): 1053-60.
[http://dx.doi.org/10.1016/S0024-3205(97)00047-7] [PMID: 9121347]
[9]
Chapple CR. Darifenacin: A novel M 3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 2004; 13(11): 1493-500.
[http://dx.doi.org/10.1517/13543784.13.11.1493] [PMID: 15500396]
[10]
Yamaguchi O. Antimuscarinics and overactive bladder: Other mechanism of action. Neurourol Urodyn 2009; 29(1): 20796.
[http://dx.doi.org/10.1002/nau.20796] [PMID: 19693952]
[11]
Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006; 45(4): 325-50.
[http://dx.doi.org/10.2165/00003088-200645040-00001] [PMID: 16584282]
[12]
Abreu-Mendes P, Silva J, Cruz F. Pharmacology of the lower urinary tract: Update on LUTS treatment. Ther Adv Urol 2020; 12: 1756287220922425.
[http://dx.doi.org/10.1177/1756287220922425] [PMID: 32489425]
[13]
Jagdale SC, Mohanty P, Chabukswar AR, Kuchekar BS. Dissolution rate enhancement, design and development of buccal drug delivery of darifenacin hydroxypropyl β-cyclodextrin inclusion complexes. J Pharm 2013; 2013: 983702.
[http://dx.doi.org/10.1155/2013/983702] [PMID: 26556003]
[14]
SreeHarsha N Shariff A, Shendkar YA, Al-Dhubiab BE, Meravanige G. Development and evaluation of a (SEDDS) self - emulsifying drug delivery system for darifenacin hydrobromide. Indian J Pharm Educ Res 2019; 53(2s): s204-12.
[http://dx.doi.org/10.5530/ijper.53.2s.67]
[15]
Abbas IK, Rajab N, A. Hussein A. Formulation and in-vitro evaluation of darifenacin hydrobromide as buccal films. Iraqi J Pharm Sci 2019; 28(2): 83-94.
[http://dx.doi.org/10.31351/vol28iss2pp83-94]
[16]
Reddy KA. K L, Basha Shaik N, B S, T H, Muliki R. Formulation and evaluation of darifenacin hydrobromide transdermal patch. Indian J Appl Res 2021; 12–14: 12-4.
[http://dx.doi.org/10.36106/ijar/5800512]
[17]
Alkilani A, McCrudden MT, Donnelly R. Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics 2015; 7(4): 438-70.
[http://dx.doi.org/10.3390/pharmaceutics7040438] [PMID: 26506371]
[18]
Kawakami K, Yoshikawa T, Moroto Y, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs. J Control Release 2002; 81(1-2): 65-74.
[http://dx.doi.org/10.1016/S0168-3659(02)00049-4] [PMID: 11992679]
[19]
El Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: Effects of cosurfactants. Int J Pharm 2008; 355(1-2): 285-92.
[http://dx.doi.org/10.1016/j.ijpharm.2007.12.022] [PMID: 18243604]
[20]
Rania Y, Dalia A. The the microemulsion as a key player in conquering the skin barrier for the aim of transdermal delivery of drugs: Reviewing a successful decade. Asian J Pharm Clin Res 2019; 34-48.
[http://dx.doi.org/10.22159/ajpcr.2019.v12i5.32444]
[21]
Prince LM. A theory of aqueous emulsions I. Negative interfacial tension at the oil/water interface. J Colloid Interface Sci 1967; 23(2): 165-73.
[http://dx.doi.org/10.1016/0021-9797(67)90099-9]
[22]
Quellet C, Eicke HF. Some comments on the gelation of gelatin containing water/oil microemulsions. J Phys Chem 1987; 91(15): 4211-2.
[http://dx.doi.org/10.1021/j100299a052]
[23]
Acharya A, Satish NK, Manoj L, Chitti R. Development and validation of RP-HPLC method for the determination of darifenacin hydrobromide in bulk drug and pharmaceutical dosage form. J Sci Eng Technol 2018; 13(1): 36-44.
[http://dx.doi.org/10.3126/kuset.v13i1.21251]
[24]
Tole K, Deshmukh G. Design and characterization of microemulsion gel for transdermal drug delivery system of duloxetine hydrochloride. Asian J Pharm Clin Res 2018; 11(11): 157.
[http://dx.doi.org/10.22159/ajpcr.2018.v11i11.27552]
[25]
Yang J, Xu H, Wu S, et al. Preparation and evaluation of microemulsion-based transdermal delivery of Cistanche tubulosa phenylethanoid glycosides. Mol Med Rep 2017; 15(3): 1109-16.
[http://dx.doi.org/10.3892/mmr.2017.6147] [PMID: 28138704]
[26]
Kajbafvala A, Salabat A. Microemulsion and microemulsion gel formulation for transdermal delivery of rutin: Optimization, in-vitro/ex-vivo evaluation and SPF determination. J Dispers Sci Technol 2022; 43(12): 1848-57.
[http://dx.doi.org/10.1080/01932691.2021.1880928]
[27]
Zhao L, Wang Y, Zhai Y, Wang Z, Liu J, Zhai G. Ropivacaine loaded microemulsion and microemulsion-based gel for transdermal delivery: Preparation, optimization, and evaluation. Int J Pharm 2014; 477(1-2): 47-56.
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.005] [PMID: 25304092]
[28]
Lalan MS, Laddha NC, Lalani J, Imran MJ, Begum R, Misra A. Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis. Drug Deliv Transl Res 2012; 2(2): 129-41.
[http://dx.doi.org/10.1007/s13346-012-0060-8] [PMID: 25786721]
[29]
Rahmawati ED, Bhagawan WS, Rizkiah F. Optimization of carbopol 940 and oleic acid in diclofenac sodium base gel using factorial design 22 method. J Islam Pharm 2018; 3(1): 15.
[http://dx.doi.org/10.18860/jip.v3i1.4993]
[30]
Hung WH, Chen PK, Fang CW, Lin YC, Wu PC. Preparation and evaluation of azelaic acid topical microemulsion formulation: In vitro and in vivo study. Pharmaceutics 2021; 13(3): 410.
[http://dx.doi.org/10.3390/pharmaceutics13030410] [PMID: 33808836]
[31]
Tirunagari M, Jangala VR, Khagga M, Gannu R. Transdermal therapeutic system of isradipine: Effect of hydrophilic and hydrophobic matrix on in vitro and Ex vivo characteristics. Arch Pharm Res 2010; 33(7): 1025-33.
[http://dx.doi.org/10.1007/s12272-010-0708-1] [PMID: 20661712]
[32]
Shewaiter MA, Hammady TM, El-Gindy A, Hammadi SH, Gad S. Formulation and characterization of leflunomide/diclofenac sodium microemulsion base-gel for the transdermal treatment of inflammatory joint diseases. J Drug Deliv Sci Technol 2021; 61(102110): 102110.
[http://dx.doi.org/10.1016/j.jddst.2020.102110]
[33]
Dellali M, Iurciuc Tincu CE, Savin CL, Spahis N, Djennad M, Popa M. Hydrogel films based on chitosan and oxidized carboxymethylcellulose optimized for the controlled release of curcumin with applications in treating dermatological conditions. Molecules 2021; 26(8): 2185.
[http://dx.doi.org/10.3390/molecules26082185] [PMID: 33920154]
[34]
Chen H, Chang X, Du D, Li J, Xu H, Yang X. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm 2006; 315(1-2): 52-8.
[http://dx.doi.org/10.1016/j.ijpharm.2006.02.015] [PMID: 16600540]
[35]
Said M, Elsayed I, Aboelwafa AA, Elshafeey AH. Transdermal agomelatine microemulsion gel: Pyramidal screening, statistical optimization and in vivo bioavailability. Drug Deliv 2017; 24(1): 1159-69.
[http://dx.doi.org/10.1080/10717544.2017.1365392] [PMID: 28831842]
[36]
Bunchongprasert K, Shao J. Cytotoxicity and permeability enhancement of Capmul®MCM in nanoemulsion formulation. Int J Pharm 2019; 561: 289-95.
[http://dx.doi.org/10.1016/j.ijpharm.2019.03.010] [PMID: 30851390]
[37]
Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces 2010; 76(2): 410-20.
[http://dx.doi.org/10.1016/j.colsurfb.2009.11.021] [PMID: 20042320]
[38]
Handa M, Ujjwal RR, Vasdev N, Flora SJS, Shukla R. Optimization of surfactant- and cosurfactant-aided pine oil nanoemulsions by isothermal low-energy methods for anticholinesterase activity. ACS Omega 2021; 6(1): 559-68.
[http://dx.doi.org/10.1021/acsomega.0c05033] [PMID: 33458508]
[39]
Chen J, Ma X, Yao G, Zhang W, Zhao Y. Microemulsion-based anthocyanin systems: Effect of surfactants, cosurfactants, and its stability. Int J Food Prop 2018; 21(1): 1152-65.
[http://dx.doi.org/10.1080/10942912.2018.1485032]
[40]
Abd Sisak MA, Daik R, Ramli S. Study on the effect of oil phase and co-surfactant on microemulsion systems. Malays J Anal Sci 2017; 21(6): 1409-16.
[http://dx.doi.org/10.17576/mjas-2017-2106-23]
[41]
Kumar A, Kushwaha V, Sharma PK. Pharmaceutical microemulsion: Formulation, characterization and drug deliveries across skin. Int J Drug Dev Res 2014; 6: 1-21.
[42]
Barot BS, Parejiya PB, Patel HK, Gohel MC, Shelat PK. Microemulsion-based gel of terbinafine for the treatment of onychomycosis: Optimization of formulation using D-optimal design. AAPS PharmSciTech 2012; 13(1): 184-92.
[http://dx.doi.org/10.1208/s12249-011-9742-7] [PMID: 22187363]
[43]
Shinde U, Pokharkar S, Modani S. Design and evaluation of microemulsion gel system of nadifloxacin. Indian J Pharm Sci 2012; 74(3): 237-47.
[http://dx.doi.org/10.4103/0250-474X.106066] [PMID: 23439454]
[44]
Wang W, Cai Y, Liu Y, Zhao Y, Feng J, Liu C. Microemulsions based on paeonol-menthol eutectic mixture for enhanced transdermal delivery: Formulation development and in vitro evaluation. Artif Cells Nanomed Biotechnol 2017; 45(6): 1-6.
[http://dx.doi.org/10.1080/21691401.2017.1389748] [PMID: 27600884]
[45]
Kim CK, Ryuu SA, Park KM, Lim SJ, Hwang SJ. Preparation and physicochemical characterization of phase inverted water/oil microemulsion containing cyclosporin A. Int J Pharm 1997; 147(1): 131-4.
[http://dx.doi.org/10.1016/S0378-5173(96)04791-6]
[46]
El Maghraby MG. Microemulsions as transdermal drug delivery systems. Curr Nanosci 2012; 8(4): 504-11.
[http://dx.doi.org/10.2174/157341312801784258]
[47]
Lalan MS, Laddha NC, Lalani J, Imran MJ, Begum R, Misra A. Dose reduction of a potent topical corticosteroid with microemulsion based cream. J Nanopharm Drug Deliv 2013; 1(1): 52-63.
[http://dx.doi.org/10.1166/jnd.2013.1008]
[48]
Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int J Pharm 2003; 254(2): 99-107.
[http://dx.doi.org/10.1016/S0378-5173(02)00632-4] [PMID: 12623186]
[49]
Hajjar B, Zier KI, Khalid N, Azarmi S, Löbenberg R. Evaluation of a microemulsion-based gel formulation for topical drug delivery of diclofenac sodium. J Pharm Investig 2018; 48(3): 351-62.
[http://dx.doi.org/10.1007/s40005-017-0327-7]
[50]
Katre Y, Singh M, Singh AK. Kinetics and mechanism of cetyltrimethylammonium bromide catalyzed n-bromosuccinimide oxidation of d-mannose in acidic medium. J Dispers Sci Technol 2011; 32(6): 903-12.
[http://dx.doi.org/10.1080/01932691003756910]
[51]
Fang C-L, Al-Suwayeh SA, Fang J-Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[52]
Lalan M, Shah P, Shah K, Prasad A. Developmental studies of curcumin nlcs as safe alternative in management of infectious childhood dermatitis. Nanosci Nanotechnol Asia 2020; 10(4): 390-403.
[http://dx.doi.org/10.2174/2210681209666181226153741]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy